HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. The company is headquartered in Southlake, Texas and currently employs 15 full-time employees. The company went IPO on 2022-06-15. The firm has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware-agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. The company delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Mr. Andrew Simpson is the Chairman of the Board of HeartSciences Inc, joining the firm since 2012.
What is the price performance of HSCS stock?
The current price of HSCS is $1.93, it has decreased 0% in the last trading day.
What are the primary business themes or industries for HeartSciences Inc?
HeartSciences Inc belongs to Health Care industry and the sector is Health Care
What is HeartSciences Inc market cap?
HeartSciences Inc's current market cap is $6.1M
Is HeartSciences Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for HeartSciences Inc, including 2 strong buy, 5 buy, 1 hold, 0 sell, and 2 strong sell